Equity Overview
Price & Market Data
Price: $6.85
Daily Change: -$1.09 / 15.91%
Range: $6.83 - $8.05
Market Cap: $7,751,115
Volume: 24,984
Performance Metrics
1 Week: -2.13%
1 Month: -42.92%
3 Months: -49.65%
6 Months: -68.92%
1 Year: -89.24%
YTD: -61.33%
Company Details
Employees: 36
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which is in Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 + HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. for two molecules constructed with its TOBI platform; and a license, research and co-development agreement with WY Biotech for its preclinical molecules which were built with the TRBC platform technology. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.